Pfizer’s Rare Heart Disease Drug Vyndaqel Turned Down by NICE

The UK’s National Institute for Health and Care Excellence (NICE) has rejected Pfizer’s Vyndaqel (tafamidis) for National Health Service use as a treatment for adults with the rare heart condition transthyretin amyloidosis with cardiomyopathy.

NICE said the drug failed to show adequate cost-effectiveness because of uncertainty “about how long the treatment works after it is stopped” and because there was “not enough evidence that recommending tafamidis would reduce diagnosis delays.”

In the UK, Vyndaqel is priced at approximately $15,100 for a 30-capsule pack of 61-mg capsules.